GINAKIT2 - Treatment for Neuroblastoma (H-41033)
GD2 Specific Chimeric Antigen Receptor and Interleukin-15 Expressing Autologous Natural Killer T-Cells to Treat Children with Neuroblastoma (GINAKIT2)
This study is for patients with a type of cancer called neuroblastoma. Neuroblastoma is a type of cancer that affects nerve cells in the nervous system. The nervous system consists of the brain, spinal cord, and the nerves that reach out from them to all areas of the body. The nervous system is essential for thinking, sensation, and movement, among other things. The patient's neuroblastoma has either come back after treatment or did not respond to the standard medicines used to treat it. Because there is no standard treatment for the patient's cancer at this time, they are being asked to volunteer in a gene transfer research study using special immune cells.
The purpose of this study is to find the largest effective and safe dose of GD2-CAR NKT cells (GINAKIT cells), to evaluate their effect on the tumor and how long they can be detected in the patient's blood and what affect they have on the patient's neuroblastoma.
NCT#/ClinicalTrials.gov ID: NCT03294954